Tacrolimus in CD3+ T Lymphocytes

Status Completed

Clinical Trial Summary

The goal of this study is to measure concentrations of the drug tacrolimus in both whole blood and within T lymphocytes. It will also learn on the correlation between the concentration in T lymphocytes and the effects of the drug. The main questions are: (i) What is the ratio between the tacrolimus concentration within T lymphocytes and in whole blood?; (ii) What is the correlation between tacrolimus concentrations and the effects of the drug? Participants will: - Receive standard clinical care; - Undergo two extra venipunctures for the collection of blood.

Clinical Trial Description

Rationale: The immunosuppressive drug tacrolimus is routinely monitored after kidney transplantation by measuring the whole blood, pre-dose concentration (C0). However, the C0 has a poor correlation with clinical events, most notably the risk of acute rejection. Since tacrolimus' site of action is within immune cells, the intracellular tacrolimus concentration in peripheral blood mononuclear cells (PBMCs) has recently been proposed to better represent the active concentration. However, several studies could not demonstrate an association between the intracellular tacrolimus concentration and acute rejection. One of the possible explanations for this surprising finding is the fact the PBMC fraction is composed of several cells including lymphocytes and monocytes. In this study, the tacrolimus concentration in CD3+ T lymphocytes will be investigated as this may be a more relevant cell population than PBMCs. Objective: To prospectively measure the intracellular tacrolimus concentration in CD3+ T lymphocytes in kidney transplant recipients. The area under the concentration-vs-time curve (AUC) of the intracellular tacrolimus concentration will be determined and used for the development of a population pharmacokinetic model. The pharmacokinetics of intra-CD3+ tacrolimus will be compared with the whole-blood concentration and will be related to important clinical events. Study design: Observational study with additional blood sampling. Study population: Twenty-five de novo kidney transplant recipients receiving once-daily tacrolimus- as maintenance immunosuppression. Intervention: Two extra venipunctures for the collection of blood. ;

Study Design

Related Conditions & MeSH terms

Immunosuppression

Clinical Trial Details

NCT number	NCT06342505
Study type	Observational
Source	Erasmus Medical Center
Contact
Status	Completed
Phase
Start date	May 30, 2022
Completion date	November 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05060991` - Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients	Phase 4
Completed	`NCT02833805` - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia	Phase 2
Completed	`NCT01252537` - Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia	N/A
Completed	`NCT01678937` - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents	N/A
Completed	`NCT00621699` - Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects	Phase 1
Completed	`NCT00788021` - Protective Immunity Project 01	N/A
Active, not recruiting	`NCT00166842` - Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets	Phase 4
Recruiting	`NCT05616130` - Pathological Myeloid Activation After Sepsis and Trauma
Completed	`NCT03117192` - Zinc Supplementation on Cellular Immunity in Thalassemia Major	Phase 4
Recruiting	`NCT01568697` - Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Not yet recruiting	`NCT06024226` - Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
Not yet recruiting	`NCT04961229` - Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response	Phase 4
Completed	`NCT03139565` - High Dose vs. Standard Influenza Vaccine in Adult SOT	Phase 3
Completed	`NCT02547753` - Dental Extractions Among Renal Transplant Recipients
Completed	`NCT01702207` - Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk	Phase 4
Completed	`NCT00626808` - A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children	Phase 4
Completed	`NCT00419575` - Renal Transplantation With Immune Monitoring	N/A
Completed	`NCT00783380` - Influenza Vaccination in Immunocompromized Patients	Phase 4
Completed	`NCT04835948` - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
Recruiting	`NCT05043870` - Combined Immunosuppression for Pediatric Crohn's Disease	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Tacrolimus in CD3+ T Lymphocytes — INTACT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms